FGFR2 and cholangiocarcinoma: The FGFR1, FGFR2, and FGFR3 selective inhibitor pemigatinib is one of the two currently approved FGFR inhibitors for the treatment of previously treated metastatic CCA with FGFR2 gene fusion or translocation [41,42].